Venus Remedies Limited has received marketing authorization from Indonesia’s drug regulator for its combination antibiotic ceftazidime + avibactam. This marks the company’s first approval in the anti-infective segment in Indonesia. It also enables the first generic launch of ceftazidime + avibactam in the country.
The approval represents a key step in Venus Remedies’ international expansion. Indonesia becomes a new growth market as Venus deepens its presence across ASEAN.
Venus Remedies is already commercially active in 10 ASEAN countries. Across the region, the company holds more than 370 injectable approvals. This authorization further consolidates its leadership in critical-care injectables.
Ceftazidime + avibactam is an advanced antibiotic combination. It is indicated for serious multidrug-resistant infections, including:
The therapy targets gram-negative pathogens such as:
Avibactam inhibits key beta-lactamase enzymes. This restores ceftazidime activity against resistant bacterial strains.
Saransh Chaudhary, President, Global Critical Care, Venus Remedies, highlighted the importance of the approval.
He stated that the milestone reflects Venus Remedies’ commitment to addressing antimicrobial resistance through hospital-focused therapies. The approval also reinforces the company’s mission to expand access to life-saving anti-infective treatments globally.
Indonesia is one of the largest pharmaceutical markets in Southeast Asia. Antibiotics remain a critical therapeutic category due to:
The broader ASEAN pharmaceutical market is projected to exceed USD 63.5 billion by 2029.
Aditi K Chaudhary, President, International Business, Venus Remedies, noted that the approval marks the company’s entry into anti-infectives in Indonesia. Until now, Venus Remedies’ presence in the country was primarily focused on oncology. Indonesia has been identified as a priority market in the company’s long-term strategy.
As the first generic ceftazidime + avibactam approved in Indonesia, the product is expected to:
This strengthens Venus Remedies’ commercial platform across ASEAN.
Asia continues to grow at over 30% year-on-year for Venus Remedies. The company remains focused on:
This strategy reinforces India’s role as a reliable supplier in the global fight against antimicrobial resistance.
Panchkula-based Venus Remedies Ltd is among the world’s top fixed-dosage injectable manufacturers. Key highlights include:
The Indonesian approval adds another critical market to Venus Remedies’ growing global footprint.